Do Joong Park1,2, An Na Seo3, Changhwan Yoon1, Geoffrey Y Ku4, Daniel G Coit1, Vivian E Strong1, Yun-Suhk Suh5, Hye Seung Lee6, Han-Kwang Yang5, Hyung-Ho Kim2, Sam S Yoon7,8. 1. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 2. Department of Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. 3. Department of Pathology, Kyungpook National University School of Medicine, Kyungpook National University Hospital, Daegu, Korea. 4. Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 5. Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea. 6. Department of Pathology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. 7. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. yoons@mskcc.org. 8. Gastric and Mixed Tumor Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. yoons@mskcc.org.
Abstract
BACKGROUND: Clinical trials of agents targeting the vascular endothelial growth factor A (VEGF-A) pathway in gastric adenocarcinoma (GA) suggest that these therapies may have varying efficacy in different races. METHODS: VEGF-A in serum and/or VEGF receptor 2 (VEGFR-2) in CD31-positive tumor vessels (VEGFR-2/CD31) were measured in 118 Caucasians and 263 Asians who underwent gastric resection at two institutions and correlated with overall survival (OS). Blood was drawn before any treatment. Patients receiving neoadjuvant treatment were excluded from VEGFR-2 analysis. RESULTS: Compared with Asians, Caucasians were older (mean age 66-73 vs 59-62 years), had more proximal tumors, and had more advanced TNM stage. In the VEGF-A cohort, Caucasians had a median VEGF-A level that was 95 % higher than that of Asians and a much higher standard deviation (88 ± 6.206 vs 45 ± 76 pg/ml, p < 0.001). The 5-year OS for patients with low versus high VEGF-A levels was 72 versus 43 % in Caucasians (p = 0.001) and 86 versus 77 % in Asians (p = 0.236). In the VEGFR-2 cohort, OS was worse in Caucasians with high VEGFR-2/CD31 levels (49 vs 73 %, p = 0.038), while there was no significant difference in OS in Asians (80 vs 90 %, p = 0.119). On multivariate analyses of significant prognostic factors (excluding treatment factors and margin status), serum VEGF-A and tumor VEGFR-2/CD31 levels were independent predictors of OS only in Caucasians. CONCLUSIONS: In patients with resectable GA, VEGF-A and VEGFR-2/CD31 levels are independent predictors of OS in Caucasians but not in Asians, suggesting varying importance of this pathway in GA progression among different races.
BACKGROUND: Clinical trials of agents targeting the vascular endothelial growth factor A (VEGF-A) pathway in gastric adenocarcinoma (GA) suggest that these therapies may have varying efficacy in different races. METHODS:VEGF-A in serum and/or VEGF receptor 2 (VEGFR-2) in CD31-positive tumor vessels (VEGFR-2/CD31) were measured in 118 Caucasians and 263 Asians who underwent gastric resection at two institutions and correlated with overall survival (OS). Blood was drawn before any treatment. Patients receiving neoadjuvant treatment were excluded from VEGFR-2 analysis. RESULTS: Compared with Asians, Caucasians were older (mean age 66-73 vs 59-62 years), had more proximal tumors, and had more advanced TNM stage. In the VEGF-A cohort, Caucasians had a median VEGF-A level that was 95 % higher than that of Asians and a much higher standard deviation (88 ± 6.206 vs 45 ± 76 pg/ml, p < 0.001). The 5-year OS for patients with low versus high VEGF-A levels was 72 versus 43 % in Caucasians (p = 0.001) and 86 versus 77 % in Asians (p = 0.236). In the VEGFR-2 cohort, OS was worse in Caucasians with high VEGFR-2/CD31 levels (49 vs 73 %, p = 0.038), while there was no significant difference in OS in Asians (80 vs 90 %, p = 0.119). On multivariate analyses of significant prognostic factors (excluding treatment factors and margin status), serum VEGF-A and tumorVEGFR-2/CD31 levels were independent predictors of OS only in Caucasians. CONCLUSIONS: In patients with resectable GA, VEGF-A and VEGFR-2/CD31 levels are independent predictors of OS in Caucasians but not in Asians, suggesting varying importance of this pathway in GA progression among different races.
Authors: Manish A Shah; Minaxi Jhawer; David H Ilson; Robert A Lefkowitz; Edric Robinson; Marinela Capanu; David P Kelsen Journal: J Clin Oncol Date: 2010-12-28 Impact factor: 44.544
Authors: Manish A Shah; Ramesh K Ramanathan; David H Ilson; Alissa Levnor; David D'Adamo; Eileen O'Reilly; Archie Tse; Robin Trocola; Lawrence Schwartz; Marinela Capanu; Gary K Schwartz; David P Kelsen Journal: J Clin Oncol Date: 2006-11-20 Impact factor: 44.544
Authors: Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman Journal: CA Cancer J Clin Date: 2011-02-04 Impact factor: 508.702
Authors: J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson Journal: N Engl J Med Date: 2001-09-06 Impact factor: 91.245
Authors: Manish A Shah; Raya Khanin; Laura Tang; Yelena Y Janjigian; David S Klimstra; Hans Gerdes; David P Kelsen Journal: Clin Cancer Res Date: 2011-03-23 Impact factor: 12.531
Authors: David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua Journal: N Engl J Med Date: 2006-07-06 Impact factor: 91.245
Authors: Lidia Kędzierska; Anna Madej-Michniewicz; Natalia Marczuk; Barbara Dołęgowska; Teresa Starzyńska; Wojciech Błogowski Journal: Am J Transl Res Date: 2020-01-15 Impact factor: 4.060
Authors: Markus Moehler; Irina Gepfner-Tuma; Annett Maderer; Peter C Thuss-Patience; Joern Ruessel; Susanna Hegewisch-Becker; Hansjochen Wilke; Salah-Eddin Al-Batran; Mohammad-Reza Rafiyan; Florian Weißinger; Hans-Joachim Schmoll; Frank Kullmann; Ludwig Fischer von Weikersthal; Jens T Siveke; Jens Weusmann; Stephan Kanzler; Carl Christoph Schimanski; Melanie Otte; Lukas Schollenberger; Jochem Koenig; Peter R Galle Journal: BMC Cancer Date: 2016-08-31 Impact factor: 4.430